In the area of Health Innovation, several research groups at PSI are engaged in the study of fundamental questions regarding biology and cancer therapy. For example, they explore the structure of proteins – extremely complex biomolecules that are responsible for many different functions in organisms. Using PSI’s large research facilities, scientists also explore processes in biological tissue in order to fully understand their function and the development of specific diseases or deterioration processes. The ultimate goal is to find medicines that allow people to live as healthy a life as possible.
Patients with specific types of cancer are treated at the proton therapy facility on the PSI campus. Radiopharmaceuticals provide cancer treatments for very small tumours distributed throughout the body.
Find out more at: Overview Health Innovation
Researchers at PSI and the ANAXAM technology transfer center have found the cause of clogging in prefilled syringes.
Daniela Kiselev talks about the upgrade planned at PSI's proton accelerator facility.
PSI researchers discover a surprising mechanism that could broaden the spectrum of therapeutic uses of botulinum toxin.
PSI researchers develop a fundamentally new method for early detection of cancer.
Scientists at PSI have used mechanical stimuli to turn connective tissue cells into stem-cell-like cells and transplanted these into damaged skin tissue. This speeds up the regeneration of the skin and the healing of wounds.
The cytoskeleton is a little marvel. Probing it promises to reveal, among other things, new possibilities for cancer therapy.
High throughput experiments will enable new structural biology users to benefit from XFEL light.
A place for cutting-edge research: PSI researchers to receive comprehensive funding from the US NIH for their brain research.
On 15 August 2023 a patient suffering from oesophageal cancer was treated with proton beam therapy at PSI – for the very first time in Switzerland.
A project that promises to improve the chances of survival for prostate cancer patients has received 2 million Swiss francs in funding.
Synchrotron light can be used in follow-up after a heart transplant to determine whether the body may be rejecting the new organ.
PSI scientists have discovered the very first step occurring in the eye when light hits the retina.
PSI researchers record a molecular film of a cancer drug fitted with a photoswitch. This opens new insights for drug developers.
TATTOOS is part of the upgrade project IMPACT. Roger Schibli explains its importance for the future of cancer treatment.
A two-part upgrade is planned for HIPA starting in 2025. Preparations are already under way.
The PSI scientists Zurab Guguchia and Kirsten Schnorr are to receive grants totalling CHF 3.1 million from the Swiss National Science Foundation for ground-breaking projects.
Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases.
From research to production – the new pharmaceutical lab at PSI supplies neighbouring hospitals with novel cancer drugs.